Skip to main content
OpenTrials
Completed

NCT Number: NCT07751328

Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device

To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Royal Melbourne Hospital, also known as RMH Parkville

Melbourne, Victoria, 3052, Australia

About this study

This study aims to identify if the Wellumio 'Axana' device, a portable 0.1T MRI, is feasible, safe and reliable for use in the hospital setting.

Primary Objective

  • To assess the safety (adverse events) and feasibility (ability to acquire a scan, in a timely manner without technical fault) of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.

Secondary Objective

  • Assess usability of the Axana device.
  • Acquire physiological data from healthy controls and hospital patients with the 'Axana' device, and hospital MRI scanners.
  • Investigate the repeatability and reproducibility of scans acquired with the Axana device within and between participants.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy Participants:

  • Adults aged 18 years or older.
  • Able to undergo an in-hospital MRI scan.
  • Able to provide informed consent.
  • Head size considered suitable for scanning with the Wellumio Axana brain scanner.

Hospital Patients:

  • Adults aged 18 years or older.
  • Presenting to hospital with an acute neurological deficit suspected to be stroke within 24 hours of symptom onset.
  • Clinical and radiological diagnosis of stroke, including ischemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage.
  • Able to undergo an in-hospital MRI scan.
  • Up to 72 hours post-acute stroke.
  • Able to provide written informed consent or, where this is not possible, informed consent provided by a legally authorised representative.
  • Head size considered suitable for scanning with the Wellumio Axana brain scanner.

Exclusion criteria

General:

  • Pregnant or breastfeeding.
  • Contraindication to neuroimaging, including any condition that prohibits MRI.
  • Presence of an implanted electro-stimulating device in the head or neck.
  • Presence of a large metallic craniofacial implant, such as a bone fixation plate or mesh. Small metallic objects, such as aneurysm coils, are acceptable.
  • Presence of an intracranial pressure monitor or another similar sensor that may compromise placement of the investigational device.
  • Inability to wear the investigational device, including because of scalp skin lesions or previous intracranial surgery.
  • Unable to lie still for the duration of the scan.
  • Any other condition or symptom that, in the investigator's judgement, prevents participation in the study.
  • Unable to provide informed consent and, where applicable, consent cannot be obtained from a legally authorised representative.

Healthy Participants:

  • History of a neurological condition, including brain tumour, previous stroke, or neurological trauma.
  • Post-study MRI findings indicating a brain condition associated with structural changes.

Treatment and study plan

Axana Scan and MRI

Diagnostic Test

Patients will be booked in for a hospital MRI scan as per standard in-hospital processes. On the day of the MRI scan, patients will have two 'Axana' device scans (Scan 1 & 2). These scans must all happen on the same day and no strict order or scans are required. There must be no more than 6 hours between the hospital MRI and 'Axana' scans. The hospital MRI performed should consist of a minimum of a T2, FLAIR, ADC, DWI and GRE.

Other names: Axana Scan, MRI scan

Primary outcomes

  1. Number of Participants With Device-Related Adverse Events

    Time frame: During the Axana scan and immediately following completion of the scan

    Number of participants experiencing one or more adverse events considered related to the Axana device or scanning procedure

  2. Proportion of Axana Scan Attempts Successfully Completed Without Technical Failure

    Time frame: During each Axana scanning session

    Proportion of attempted Axana scans successfully completed without a technical fault preventing scan acquisition

  3. Time Required to Complete an Axana Scan

    Time frame: During each Axana scanning session

    Elapsed time, measured in minutes, required to complete an Axana scan

Secondary outcomes

  1. User-Reported Usability of the Axana Device

    Time frame: Immediately after each Axana scanning session

    Usability of the Axana device assessed using a post-scan questionnaire completed by the physician or device user. Questionnaire responses were collected throughout enrolment to evaluate user experience and changes associated with increasing familiarity with the device.

  2. Agreement Between Axana and Hospital MRI Findings

    Time frame: Axana and hospital MRI examinations performed on the same day, with no more than 6 hours between examinations

    Agreement between findings obtained using the Axana device and findings from the hospital MRI examination performed on the same day

  3. Within-Participant Repeatability of Axana Scans

    Time frame: Day 1 During the same Axana scanning session

    Repeatability of Axana scan findings assessed by comparing repeated Axana scans acquired from the same participant during the same scanning session

Sponsors and collaborators

Lead sponsor

Wellumio R&D Australia Pty Ltd

Industry

Registry information

Official study title

Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable Magnetic Resonance Imaging Device The 'Portable MRI Study'

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 7, 2026
Registry last updated
Aug 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.